Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial

Mary Gleeson; Nicholas Counsell; David Cunningham; Anthony Lawrie; Laura Clifton-Hadley; Eliza Hawkes; Andrew McMillan; Kirit M. Ardeshna; Cathy Burton; Nick Chadwick; Joanna Gambell; Paul Smith; Paul Mouncey; Christopher Pocock; John Radford; John Davies; Deborah Turner; Anton Kruger; Peter Johnson; David Linch

doi:10.1111/bjh.16691

Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Anthony Lawrie, Laura Clifton-Hadley, Eliza Hawkes, Andrew McMillan, Kirit M. Ardeshna, Cathy Burton, Nick Chadwick, Joanna Gambell, Paul Smith, Paul Mouncey, Christopher Pocock, John Radford, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David Linch

Research output: Contribution to journal › Article › Research › peer-review

18 Citations (Scopus)

Abstract

We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.

Original language	English
Pages (from-to)	1015-1019
Number of pages	5
Journal	British Journal of Haematology
Volume	192
Issue number	6
DOIs	https://doi.org/10.1111/bjh.16691
Publication status	Published - Mar 2021
Externally published	Yes

Keywords

clinical trials
diffuse large B-cell lymphoma
international prognostic index
rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.16691

Cite this

Gleeson, M., Counsell, N., Cunningham, D., Lawrie, A., Clifton-Hadley, L., Hawkes, E., McMillan, A., Ardeshna, K. M., Burton, C., Chadwick, N., Gambell, J., Smith, P., Mouncey, P., Pocock, C., Radford, J., Davies, J., Turner, D., Kruger, A., Johnson, P., & Linch, D. (2021). Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. British Journal of Haematology, 192(6), 1015-1019. https://doi.org/10.1111/bjh.16691

@article{af20c3f4b3ef4f4282fe32c3dabcb139,

title = "Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial",

abstract = "We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Espa{\~n}ol de Linfomas/Transplante de M{\'e}dula {\'O}sea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.",

keywords = "clinical trials, diffuse large B-cell lymphoma, international prognostic index, rituximab",

author = "Mary Gleeson and Nicholas Counsell and David Cunningham and Anthony Lawrie and Laura Clifton-Hadley and Eliza Hawkes and Andrew McMillan and Ardeshna, \{Kirit M.\} and Cathy Burton and Nick Chadwick and Joanna Gambell and Paul Smith and Paul Mouncey and Christopher Pocock and John Radford and John Davies and Deborah Turner and Anton Kruger and Peter Johnson and David Linch",

year = "2021",

month = mar,

doi = "10.1111/bjh.16691",

language = "English",

volume = "192",

pages = "1015--1019",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

Gleeson, M, Counsell, N, Cunningham, D, Lawrie, A, Clifton-Hadley, L, Hawkes, E, McMillan, A, Ardeshna, KM, Burton, C, Chadwick, N, Gambell, J, Smith, P, Mouncey, P, Pocock, C, Radford, J, Davies, J, Turner, D, Kruger, A, Johnson, P & Linch, D 2021, 'Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial', British Journal of Haematology, vol. 192, no. 6, pp. 1015-1019. https://doi.org/10.1111/bjh.16691

Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. / Gleeson, Mary; Counsell, Nicholas; Cunningham, David et al.
In: British Journal of Haematology, Vol. 192, No. 6, 03.2021, p. 1015-1019.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Prognostic indices in diffuse large B-cell lymphoma in the rituximab era

T2 - an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial

AU - Gleeson, Mary

AU - Counsell, Nicholas

AU - Cunningham, David

AU - Lawrie, Anthony

AU - Clifton-Hadley, Laura

AU - Hawkes, Eliza

AU - McMillan, Andrew

AU - Ardeshna, Kirit M.

AU - Burton, Cathy

AU - Chadwick, Nick

AU - Gambell, Joanna

AU - Smith, Paul

AU - Mouncey, Paul

AU - Pocock, Christopher

AU - Radford, John

AU - Davies, John

AU - Turner, Deborah

AU - Kruger, Anton

AU - Johnson, Peter

AU - Linch, David

PY - 2021/3

Y1 - 2021/3

N2 - We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.

AB - We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.

KW - clinical trials

KW - diffuse large B-cell lymphoma

KW - international prognostic index

KW - rituximab

UR - https://www.scopus.com/pages/publications/85084993000

U2 - 10.1111/bjh.16691

DO - 10.1111/bjh.16691

M3 - Article

C2 - 32436212

AN - SCOPUS:85084993000

SN - 0007-1048

VL - 192

SP - 1015

EP - 1019

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this